{"id":"phase-1-aripiprazole","safety":{"commonSideEffects":[{"rate":"10-25%","effect":"Akathisia"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Anxiety"},{"rate":"5-15%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing dopaminergic stabilization by increasing activity when dopamine is low and decreasing it when dopamine is high. It also has antagonist activity at serotonin 5-HT7 receptors and partial agonist activity at 5-HT1A receptors, contributing to its antipsychotic and mood-stabilizing effects.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:39.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Autism spectrum disorder (irritability)"}]},"trialDetails":[{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT03874494","phase":"PHASE3","title":"Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2019-11-27","conditions":"Schizophrenia","enrollment":371},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06589817","phase":"PHASE3","title":"A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2024-10","conditions":"Acute Schizophrenia","enrollment":376},{"nctId":"NCT02918370","phase":"PHASE3","title":"Aripiprazole for Bipolar Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-11","conditions":"Bipolar Disorder, Alcoholism, Alcohol Abuse","enrollment":75},{"nctId":"NCT03522168","phase":"","title":"Long-term Antipsychotic Pediatric Safety Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-10","conditions":"Weight, Body","enrollment":509},{"nctId":"NCT04030143","phase":"PHASE1, PHASE2","title":"A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-01","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":266},{"nctId":"NCT02357849","phase":"PHASE4","title":"Fluoxetine vs Aripiprazole Comparative Trial (FACT)","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2014-07","conditions":"Attenuated Psychosis Syndrome","enrollment":9},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT01328093","phase":"PHASE3","title":"A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients","status":"TERMINATED","sponsor":"Denovo Biopharma LLC","startDate":"2011-04","conditions":"Schizophrenia","enrollment":678},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT01111539","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-13","conditions":"Major Depressive Disorder (MDD)","enrollment":211},{"nctId":"NCT03892889","phase":"PHASE3","title":"A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-04-29","conditions":"Schizophrenia","enrollment":277},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT03661983","phase":"PHASE4","title":"Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-13","conditions":"Tourette's Disorder (TD)","enrollment":36},{"nctId":"NCT03172871","phase":"PHASE3","title":"Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2017-05-15","conditions":"Schizophrenia","enrollment":436},{"nctId":"NCT03345979","phase":"PHASE3","title":"A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-11-15","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02320032","phase":"PHASE1","title":"An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2014-12","conditions":"Schizophrenia","enrollment":140},{"nctId":"NCT03150771","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-14","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT00194012","phase":"PHASE3","title":"Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-08","conditions":"Bipolar Disorder","enrollment":62},{"nctId":"NCT00226317","phase":"NA","title":"Aripiprazole in the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Cambridge Health Alliance","startDate":"2004-04","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02526030","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2008-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02305823","phase":"PHASE4","title":"Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","startDate":"2005-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":203},{"nctId":"NCT02636842","phase":"PHASE1","title":"A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-12","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":47},{"nctId":"NCT01122927","phase":"PHASE3","title":"Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07","conditions":"Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features","enrollment":524},{"nctId":"NCT00905307","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-07","conditions":"Schizophrenia","enrollment":459},{"nctId":"NCT01432444","phase":"PHASE3","title":"Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-09","conditions":"Schizophrenia","enrollment":493},{"nctId":"NCT01149655","phase":"PHASE3","title":"Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07","conditions":"Schizophrenia","enrollment":252},{"nctId":"NCT01509053","phase":"PHASE3","title":"Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-01","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT01663532","phase":"PHASE3","title":"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-10","conditions":"Schizophrenia","enrollment":340},{"nctId":"NCT00194077","phase":"PHASE3","title":"Study of Aripiprazole (Abilify) in Children With Symptoms of Mania","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-08","conditions":"Bipolar Disorder","enrollment":60},{"nctId":"NCT00221962","phase":"PHASE4","title":"Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2005-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01227668","phase":"PHASE4","title":"Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Irritability Associated With Autistic Disorder","enrollment":215},{"nctId":"NCT02040883","phase":"PHASE4","title":"Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia","status":"UNKNOWN","sponsor":"Qingyun Yin","startDate":"2014-02","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT01438060","phase":"PHASE3","title":"Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2000-08","conditions":"Dementia, Alzheimer Type","enrollment":232},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00095758","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00095823","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00094432","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-06","conditions":"Bipolar I Disorder","enrollment":650},{"nctId":"NCT00300846","phase":"PHASE4","title":"A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00102518","phase":"PHASE3","title":"Aripiprazole Open-Label, Safety and Tolerability Study","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-09","conditions":"Schizophrenia, Bipolar Disorder","enrollment":325},{"nctId":"NCT00110461","phase":"PHASE3","title":"Aripiprazole in Children and Adolescents With Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-03","conditions":"Bipolar Disorder","enrollment":296},{"nctId":"NCT00580125","phase":"PHASE2","title":"Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Schizophrenia","enrollment":164},{"nctId":"NCT00573716","phase":"","title":"Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents","status":"COMPLETED","sponsor":"Creighton University","startDate":"2006-10","conditions":"Psychiatry","enrollment":60},{"nctId":"NCT00545675","phase":"PHASE4","title":"Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-12","conditions":"Bipolar Disorder","enrollment":146},{"nctId":"NCT01075373","phase":"","title":"A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2009-03","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00352339","phase":"PHASE4","title":"The New Strategy for Pharmacological Treatment in People With Schizophrenia","status":"UNKNOWN","sponsor":"Inje University","startDate":"2006-08","conditions":"Schizophrenia","enrollment":90},{"nctId":"NCT00689559","phase":"PHASE1","title":"Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-03","conditions":"Alzheimer's Disease","enrollment":52},{"nctId":"NCT00528359","phase":"","title":"β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2005-10","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT00440713","phase":"PHASE3","title":"Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2004-01","conditions":"Posttraumatic Stress Disorder","enrollment":40},{"nctId":"NCT00102479","phase":"PHASE2","title":"Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia, Mania","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":255,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 1: Aripiprazole","genericName":"Phase 1: Aripiprazole","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}